

## Anesthesia recommendations for patients suffering from **Macrophage activation syndrome**

**Disease name:** Macrophage activation syndrome

**ICD 10:** D76.2

**Synonyms:** haemophagocytic lymphohistiocytosis, reactive haemophagocytic syndrome, hemophagocytic syndrome

Macrophage activation syndrome (MAS) is a life-threatening complication of rheumatic disease that, for unknown reasons, occurs much more frequently in individuals with systemic juvenile idiopathic arthritis (SJIA) and in those with adult-onset Still disease. Macrophage activation syndrome is characterized by pancytopenia, liver insufficiency, coagulopathy, and neurologic symptoms and is thought to be caused by the activation and uncontrolled proliferation of T lymphocytes and well-differentiated macrophages, leading to widespread hemophagocytosis and cytokine overproduction.

The incidence of MAS is unknown as there is a wide spectrum of clinical manifestations, and episodes may remain unrecognized.

---

Medicine in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnostic is wrong

---



Find more information on the disease, its centres of reference and patient organisations on Orphanet: [www.orpha.net](http://www.orpha.net)

---

## Disease summary

---

Recent findings in hemophagocytic lymphohistiocytosis, a disease that is clinically similar to MAS, highlight the possible pathogenetic role of a defective function of perforin, a protein involved in the cytolytic processes and control of lymphocyte proliferation.

Primary MAS is the most typical manifestation of rare autosomal-recessively inherited disorders due to several genetic defects involved in granule-mediated cytotoxicity, killing of infected cells and termination of immunologic responses. It has been shown that mutations of the perforin gene (PRF-1,10q21) can explain 20-40% of primary forms of MAS.

Secondary or acquired forms of MAS can break out at any time during the course of a primitive disease and occasionally it might be its presenting manifestation. In cases of acquired MAS no underlying immunologic deficiency can be identified. Acquired forms of MAS are most frequent in children with systemic onset-juvenile idiopathic arthritis: some authors suggest an association rate of 5-10% and MAS is believed to contribute significantly to mortality rate in this category of juvenile idiopathic arthritis.

Both primary and acquired forms of MAS can be triggered by viral, bacterial, fungal infections, parasitic infestations or specific drug administrations

Although the clinical features of MAS have been well documented, early diagnosis can be difficult. Measurement of the serum ferritin level may assist in the diagnosis and may be a useful indicator of disease activity, therapy response, and prognosis. The recognition that MAS belongs to the secondary or reactive hemophagocytic syndromes has led to the proposal to rename it according to the contemporary classification of histiocytic disorders.

The principle challenge for treating patients with HLH is making a timely diagnosis. It is also critical to search for and treat underlying triggers of HLH, and institute specific antimicrobial therapy.

Although HLH appears to be a disease of excessive immune activation, the ideal form of immune suppression/anti-inflammatory therapy remains unknown. Although somewhat responsive to corticosteroids and clearly responsive to etoposide or anti-T-cell serotherapy (ATG or alemtuzumab), HLH remains difficult to treat. Generally, HCT is recommended in the case of documented familial HLH, recurrent or progressive disease despite intensive therapy, and CNS involvement

---

## Typical surgery

---

Bone marrow aspirate, long term central venous catheter positioning, pleuric tube positioning, abdominal tube positioning, liver biopsy.

Other incidental surgeries apart from disease or for diagnosis may also be required in such children.

---

## Type of anaesthesia

---

There is no definite recommendation for either general or regional anaesthesia, notwithstanding macrophage activation syndrome starts often with very low platelet count

and reduced coagulation activity due to liver failure. In order to perform safe anesthesia, regional anesthesia should be avoided.

The main concerns in patient with MAS are its perioperative risk of flare and thus avoidance of trigger factors. The role of anesthetic drugs as trigger factor for MAS has not been reported in literature.

In SoJIA, MAS is a life-threatening complication and accounts for a significant proportion of the morbidity and mortality (8–22%). It is triggered by viral infections, drugs [Non-steroidal anti-inflammatory agent (NSAID), disease-modifying agents such as gold salts, sulphasalazine and penicillamine] and external stresses such as exposure to cold.

The anaesthetic drugs that are histamine releasers such as morphine and atracurium needs to be avoided.

Various trigger factors (NSAIDs, drugs releasing histamine and cold) that may lead to MAS need to be avoided in the perioperative period. Elective procedures should be scheduled during remission phase of disease.

---

#### **Necessary additional diagnostic procedures (preoperative)**

---

Cardiac function tests like electrocardiography and echocardiography.

Blood examinations, enlarged metabolic or coagulation tests, Lactate blood level, kidney function exams.

BNP blood level is useful to monitor cardiac failure.

X-ray of the thorax, lung ultrasound, blood gas analyzes to focus on atelectasis, pleural fluid effusion and PaO<sub>2</sub>/FiO<sub>2</sub>.

Consultation of a specialist to document for juridical reasons already existent deficits, e.g. of neurological nature.

---

#### **Particular preparation for airway management**

---

There are not reported particular difficulties in airway management.

---

#### **Particular preparation for transfusion or administration of blood products**

---

Assure availability of fresh frozen plasma, platelet and concentrated red cells, tranexamic acid and coagulation factors may be necessary.

---

### **Particular preparation for anticoagulation**

---

There is no evidence to support the need of particular anticoagulation. But the impaired mobility of severe clinical presentation may suggest a higher risk of postoperative thrombosis.

---

### **Particular precautions for positioning, transport or mobilisation**

---

Not reported, related to haemodynamic instability.

---

### **Probable interaction between anaesthetic agents and patient's long term medication**

---

Not reported.

---

### **Anaesthesiologic procedure**

---

In case of present cardiac failure and /or pericardiac effusion avoid nitrous oxide because of cardio-depressant effects.

Inotropic drug support is required usually.

Opiates, propofol and local anaesthetics have been used without any complication. Patients may require a lower dose of propofol or opiates.

Hoffman's reaction dependent drugs such Remifentanil and Cis-Atracurium are suggested to facilitate drugs' metabolism and elimination.

Mechanical ventilation or non invasive ventilation are recommended to limit atelectasis development.

---

### **Particular or additional monitoring**

---

Monitor body temperature to avoid hypertermia and increased oxygen demand.

Due to MAS life threatening nature, arterial cannulation for invasive blood pressure measurement and central venous line placement is recommended. In case of cardiac failure, transesophageal echocardiography and SviO<sub>2</sub> catheter are very useful.

---

### **Possible complications**

---

Patients with MAS are at risk for acute cardiac, respiratory and renal failure so far it is known as multi organ failure syndrome.

Sedative drugs (benzodiazepines) can worsen respiratory insufficiency.

---

### **Postoperative care**

---

Degree of postoperative monitoring is depending on surgical procedure and preoperative condition of the patient. Intensive care is mandatory.

---

### **Information about emergency-like situations / Differential diagnostics**

---

caused by the illness to give a tool to distinguish between a side effect of the anaesthetic procedure and a manifestation of the diseases, e.g.:

Not reported.

---

### **Ambulatory anaesthesia**

---

-

---

### **Obstetrical anaesthesia**

---

Is requested to follow general anaesthesia recommendations.

## Literature and internet-links

1. Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. *Br J Haematol*. 2013 Jun;161(5):609-22. doi: 10.1111/bjh.12293. Epub 2013 Apr 12.
2. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis *Blood*. 2011 Oct 13;118(15):4041-52. doi: 10.1182/blood-2011-03-278127.
3. GROM AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome and hemophagocytic lymphohistiocytosis? *Arthritis Rheum* 2004; 50: 689-698.
4. STEPHAN JL, ZELLER J, HUBERT P, HERBELIN C, DAYER JM, PRIEUR AM. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. *Clin Exp Rheumatol* 1993; 11: 451-456.
5. ATHREYA BH. Is macrophage activation syndrome a new entity? *Clin Exp Rheumatol* 2002, 20: 121-123.
6. RAMANAN AV, BAILDAM EM. Macrophage activation syndrome is hemophagocytic lymphohistiocytosis: need for the right terminology. *J Rheumatol* 2002; 29: 1105.
7. RAMANAN AV, SCHNEIDER R. Macrophage activation syndrome—what's in a name! *J Rheumatol* 2003; 30: 2513-2516.
8. IMASHUKU S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. *Int J Hematol* 1997; 66: 135-151.
9. JANKA GE, SCHNEIDER EM. Modern management of children with haemophagocytic lymphohistiocytosis. *Br J Haematol* 2004; 124: 4-14.
10. SAWHNEY S, WOO P, MURRAY KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. *Arch Dis Child* 2001; 85: 421-426.
11. HENTER J, TONDINI C, PRITCHARD J. Histiocyte disorders. *Crit Rev Oncol Hematol* 2004; 50: 157-174.
12. TSUDA H. Hemophagocytic syndrome (HPS) in children and adults. *Int J Hematol* 1997; 65: 215-226.
13. EMMENEGGER U, SCHAER D, LARROCHE C, NEFTEL KA. Haemophagocytic syndromes in adults: current concepts and challenges ahead. *Swiss Med Wkly* 2005; 135: 299-314.
14. FISHMAN D. Hemophagocytic syndromes and infection. *Emerg Infect Dis* 2000; 6: 601-608.
15. RAVELLI A, CARIA MC, BURATTI S, MALATTIA C, TEMPORINI F, MARTINI A. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. *J Rheumatol* 2001; 28: 865-867.
16. RAMANAN AV, SCHNEIDER R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. *J Rheumatol* 2003; 30: 401-403.
17. TSAN MF, MEHLMAN DJ, GREEN RS, BELL WR. Dilantin, agranulocytosis and phagocytic marrow histiocytosis. *Ann Intern Med* 1976; 84: 710-711.
18. GOULET O, GIROT R, MAIER-REDELSPERGER M, BOUGLE D, VIRELIZIER JL, RICOUR C. Hematologic disorders following prolonged use of intravenous fat emulsions in children. *JPEN* 1986; 10: 284-288.
19. RAVELLI A. Macrophage activation syndrome. *Curr Opin Rheumatol* 2002; 14: 548-552.
20. STEPHAN JL, KONÉ-PAUT I, GALAMBRUN C, MOUY R, BADER-MEUNIER B, PRIEUR AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. *Rheumatology* 2001; 40: 1285-1292.
21. LARROCHE C, MOUTHON L. Pathogenesis of hemophagocytic syndrome. *Autoimmunity Rev* 2004; 3: 69-75.
22. GROM AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? *Curr Opin Rheumatol* 2003; 15: 587-590.
23. KOGAWA K, LEE SM, VILLANUEVA J, MARMER D, SUMEGI J, FILIPOVICH AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. *Blood* 2002; 99: 61-66.
24. ARICÒ M, DANESINO C, PENDE D, MORETTA L. Pathogenesis of haemophagocytic lymphohistiocytosis. *Br J Haematol* 2001; 114: 761-769.
25. VILLANUEVA J, LEE S, GIANNINI E, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. *Arthritis Res Ther* 2005; 7: R30-R37.

26. STEPP SE, MATHEW PA, BENNETT M, DE SAINT BASILE G, KUMAR V. Perforin: more than just an effector molecule. *Immunol Today* 2000; 21: 254-256.
27. WULFFRAAT NM, RIJKERS GT, ELST E, et al. Reduced perforin expression in systemic juvenile rheumatoid arthritis is restored by autologous stem-cell transplantation. *Rheumatology* 2003; 42: 375- 379.
28. GROM AA, VILLANUEVA J, LEE S, GOLDMUNTZ E, PASSO MH, FILIPOVICH A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. *J Pediatr* 2003; 142: 292-296.
29. SILVERMAN ED, MILLER JJ, BERNSTEIN B, SHAFAI T. Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. *J Pediatr* 1983; 103: 872-876.
30. MOUY R, STEPHAN JL, PILLET P, HADDAD E, HUBERT P, PRIEUR AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. *J Pediatr* 1996; 129: 750-754.
31. PRAHALAD S, BOVE K, DICKENS D, LOVELL DJ, GROM AA. Etanercept in the treatment of macrophage activation syndrome. *J Rheumatol* 2001; 28: 2120-2124.
32. HENTER JI, ELINDER G, OST A. The fh1 study group of the histiocyte society. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. *Semin Oncol* 1991; 18: 29-33.
33. EMMENEGGER U, REIMERS A, FREY U, et al. Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. *Swiss Med Wkly* 2002; 132: 230-236.
34. PELKONEN P, SWANLJUNG D, SIIMES A. Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. *Acta Paediatr Scand* 1986; 75: 64-68.
35. RAVELLI A, MAGNI-MANZONI S, PISTORIO A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. *J Pediatr* 2005; 146: 598-604.
36. HENTER JI, ARICÒ M, EGELER M, et al. HLH 94: a treatment protocol for hemophagocytic lymphohistiocytosis. *Med Pediatr Oncol* 1997; 28: 342-347.
37. HENTER JI, SAMUELSSON-HORNE A, ARICÒ M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. *Blood* 2002; 100: 2367- 2373.
38. SEIDEL MG, KASTNER U, MINKOW M, GADNER H. IVIG treatment of adenovirus infection associated macrophage activation syndrome in a two years old boy: case report and review of literature. *Pediatr Hematol Oncol* 2003; 20: 445-451.
39. IMASHUKU S. Clinical features and treatment strategies of Epstein-Barr virus associated hemophagocytic lymphohistiocytosis. *Crit Rev Oncol Hematol* 2002; 44: 259-272.
40. STEPHAN JL, DONADIEU J, LEDEIST F, BLANCHE S, GRISCELLI C, FISCHER A. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids and cyclosporine A. *Blood* 1993; 82: 2319-2323.
41. MATSUMOTO Y, NANIWA D, BANNO S, SUGIURA Y. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. *Ther Apher* 1998; 2: 300-304.
42. Martine Szyper-Kravitz MD. The Hemophagocytic Syndrome/Macrophage Activation Syndrome: A Final Common Pathway of a Cytokine Storm. *IMAJ • VOL 11 • october 2009*
43. Leticia Castillo, MD; Joseph Carcillo, MD. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. *Pediatr Crit Care Med* 2009 Vol. 10, No. 3
44. E. Rossetti, et al. Extracorporeal membrane oxygenation in a 10-year-old girl with macrophage activation syndrome. *Pediatr Anesth.* 2012 Sep;22(9):937-8. doi:10.1111/j.1460-9592.2012.03909.x.

---

**Last date of modification: October 2013**

---

*These guidelines have been prepared by:*

**Author**

**Dr. Emanuele Rossetti**, anaesthesiologist, Bambino Gesù Children's Hospital, IRCCS Rome, Italy

[emanuele.rossetti@opbg.net](mailto:emanuele.rossetti@opbg.net)

**Peer revision 1**

**Dr. Rakesh Garg**, anaesthesiologist, All India Institute of Medical Sciences, New Delhi, India

[drargarg@hotmail.com](mailto:drargarg@hotmail.com)

**Peer revision 2**

**Prof. Antonio Cascio**, infectious disease specialist, Azienda Ospedaliera Universitaria Policlinico "G. Martino", University of Messina, Messina, Italy

[acascio@unime.it](mailto:acascio@unime.it)

---